The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
 
Marcello Tiseo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Otsuka; Pierre Fabre
Research Funding - ARIAD
 
Sanjay Popat
Consulting or Advisory Role - ARIAD; Pfizer
 
Scott N. Gettinger
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen
Research Funding - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Incyte; Pfizer; Roche/Genentech
 
Solange Peters
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
Jeff Haney
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD